Challenges and Opportunities for Non-antibody Scaffold Drugs

Overview

Journal Drug Discov Today

Specialty Pharmacology

Date 2015 Sep 12

PMID 26360055

Citations 107

Authors

Rodrigo Vazquez-Lombardi

Tri Giang Phan

Carsten Zimmermann

David Lowe

Lutz Jermutus

Daniel Christ

Affiliations

Soon will be listed here.

Abstract

The first candidates from the promising class of small non-antibody protein scaffolds are now moving into clinical development and practice. Challenges remain, and scaffolds will need to be further tailored toward applications where they provide real advantages over established therapeutics to succeed in a rapidly evolving drug development landscape.

Citing Articles

Design of high-affinity binders to immune modulating receptors for cancer immunotherapy.

Yang W, Hicks D, Ghosh A, Schwartze T, Conventry B, Goreshnik I Nat Commun. 2025; 16(1):2001.

PMID: 40011465 PMC: 11865580. DOI: 10.1038/s41467-025-57192-z.

Molecular Display of the Animal Meta-Venome for Discovery of Novel Therapeutic Peptides.

Hsiao M, Miao Y, Liu Z, Schutze K, Limjunyawong N, Chien D Mol Cell Proteomics. 2025; 24(2):100901.

PMID: 39746545 PMC: 11833617. DOI: 10.1016/j.mcpro.2024.100901.

Generating a mirror-image monobody targeting MCP-1 via TRAP display and chemical protein synthesis.

Hayashi G, Naito T, Miura S, Iwamoto N, Usui Y, Bando-Shimizu M Nat Commun. 2024; 15(1):10723.

PMID: 39715753 PMC: 11666718. DOI: 10.1038/s41467-024-54902-x.

Development of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase.

Schmidt N, Kumar A, Korf L, Dinh-Fricke A, Abendroth F, Koide A Nat Commun. 2024; 15(1):10724.

PMID: 39715735 PMC: 11666773. DOI: 10.1038/s41467-024-54901-y.

Novel anti-CEA affibody for rapid tumor-targeting and molecular imaging diagnosis in mice bearing gastrointestinal cancer cell lines.

Shao H, Lv K, Wang P, Jin J, Cai Y, Chen J Front Microbiol. 2024; 15:1464088.

PMID: 39444679 PMC: 11496145. DOI: 10.3389/fmicb.2024.1464088.